Moderately to Severely Active Crohn's Disease (DBCOND0093405)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Adalimumab	A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.	Tumor necrosis factortarget
Infliximab	A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.	Tumor necrosis factortarget
Upadacitinib	An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.	Tyrosine-protein kinase JAK1target Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter
Vedolizumab	An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults.	Integrin alpha-4target Integrin beta-7target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03357471	Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Certolizumab pegol	treatment	3	completed
NCT06257706	VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease	Vedolizumab	treatment	4	recruiting